Aravind Sanjeevaiah, MD
Medical Oncology · Waxahachie, TXNPI 1093913196
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,088 of the $1,694 with a category attached, or 64.2%. Incyte Corporation accounts for 65.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,105 and has fallen 76.0% since, to $265 in 2025. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 22 payments — averaging $77.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$1K
- Pfizer$114
- E.r. Squibb & Sons, L.L.C.$108
- Sumitomo Pharma America, Inc.$102
- Astellas Pharma US Inc$93
- Novartis$39
- plus $122 from 5 others
Across 81 payments — averaging $5745.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$396K
- EMD Serono, Inc.$52K
- Ares Trading SA$10K
- Incyte Corporation$7K
- Merck$500
What the payments were for
- Speaking & faculty fees$1,08864%
- Food & beverage$60636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 3 | $1,115 |
| Pfizer | 4 | $114 |
| E.r. Squibb & Sons, L.L.C. | 5 | $108 |
| Sumitomo Pharma America, Inc. | 1 | $102 |
| Astellas Pharma US Inc | 1 | $93 |
| Novartis | 2 | $39 |
| Gilead | 2 | $38 |
| AstraZeneca | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $24 |
| Caris MPI, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$102
How this compares
$1,694 in reported general payments places this provider in the 30th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 19 | $305,584 |
| InlytaAxitinib | 11 | $289,758 |
| XtandiEnzalutamide | 19 | $199,425 |
| RevlimidLenalidomide | 12 | $172,506 |
| Lenalidomide | 12 | $151,959 |
| Abiraterone Acetate | 21 | $78,536 |
| EliquisApixaban | 115 | $75,219 |
| Imatinib Mesylate | 13 | $22,422 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 108 | $2,023 |
| Dexamethasone | 84 | $1,139 |
| Fentanyl | 11 | $1,037 |
| Ondansetron Hcl | 126 | $1,036 |
| Letrozole | 74 | $974 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 60 | $768 |
| Morphine Sulfate ErMorphine Sulfate | 32 | $646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Eliquis | $114 | $364,977126 claims |
| AstraZenecaTagrisso | $25 | $305,58419 claims |
| Astellas Pharma US IncXtandi | $93 | $199,42519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Waxahachie
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.